Dr. Sébastien Fortin PhD is a regular researcher at the Centre de recherche du CHU de Québec-Laval University, Director of a pharmaceutical chemistry laboratory located at the Hôpital Saint-François d’Assise, and Associate Professor at Laval University’s School of Pharmacy. He is author and co-author of 28 publications and co-inventor of 3 patents on the technologies that he develops. Dr. Fortin is the recipient of several awards and honors, including the Jean-François St-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research (CIHR) and the 2011 award for the best doctorate in cotutelle awarded by the Ministère des Relations internationales and the Consulat général de France à Québec. His research focuses on the design and development of new anticancer agents for use in personalized medicine.

Development of new drugs for personalized cancer chemotherapy

In Canada, cancer is the leading cause of death, followed only by cardiovascular diseases. Cancer is therefore a major public health problem. Despite recent medical breakthroughs, the ability to cure all cancer patients remains elusive. Consequently, we need to develop new treatments that will be more efficient, and more selective against cancer tumors, with the aim of improving the life expectancy and the quality of life of cancer patients. The aim of my research program is to design and prepare new anticancer agents exhibiting optimal biopharmaceutical and anticancer properties suitable for preclinical and clinical studies. My research themes are divided in two parts: 1) development of new inhibitors of DNA repair and replication mechanisms and 2) development of new inhibitors targeting cells deficient in homologous recombination. My research programs involve and focus on several interrelated and complementary disciplines, including molecular design and modeling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to the development of new, efficient and personalized anticancer treatments.

Hôpital Saint-François d'Assise
10, rue de l'Espinay
D0-705C
Québec, Québec
Canada G1L 3L5
+1 418-525-4444, extension 52364
+1 418-525-2372
Sebastien.Fortin@crchudeq... sebastien.fortin@pha.ulav...

Latest news

42 entries « ‹ 3 of 5 › »

Fortin S, Wei Lianhu, Kotra LP, C-Gaudreault R

Novel Cytocidal Substituted Phenyl 4-(2-Oxoimidazolidin-1-yl) Benzenesulfonates and Benzenesulfonamides with Affinity to the Colchicine-Binding Site: Is the Phenyl 2-Imidazolidinone Moiety a New Haptophore for the Design of New Antimitotics?

Journal Article

Open J Med Chem, 5 , 2014.

| Links:

Marceau F, Bouthillier J, Houle Steeve, Sabourin T, Fortin JP, Morissette G, Lodge R, Fortin S, C-Gaudreault R, Bawolak MT, Koumbadinga MT, Gérémy A, Roy C, Charest-Morin X, Gera L

Bradykinin receptors: agonists, antagonists, expression, signaling and adaptation to sustained stimulation

Journal Article

J Angioedema, 1 (December), 2013.

Fortin S, Berube G

Advances in the development of hybrid anticancer drugs

Journal Article

Expert Opin Drug Discov, 8 (8), 2013.

Abstract | Links:

Fortin S, Brasseur K, Morin N, Asselin E, Berube G

New platinum(II) complexes conjugated at position 7α of 17β-acetyl-testosterone as new combi-molecules against prostate cancer: design, synthesis, structure-activity relationships and biological evaluation

Journal Article

Eur J Med Chem, 68 , 2013.

Abstract | Links:

Charest-Morin X, Fortin S, Lodge R, Roy C, Gera L, C-Gaudreault R, Gaudreault RC, Marceau F

Inhibitory effects of cytoskeleton disrupting drugs and GDP-locked Rab mutants on bradykinin B₂ receptor cycling

Journal Article

Pharmacol Res, 71 , 2013.

Abstract | Links:

Saha P, Descoteaux C, Brasseur K, Fortin S, Leblanc V, Parent S, Asselin E, Berube G

Synthesis, antiproliferative activity and estrogen receptor α affinity of novel estradiol-linked platinum(II) complex analogs to carboplatin and oxaliplatin. Potential vector complexes to target estrogen-dependent tissues

Journal Article

Eur J Med Chem, 48 , 2012.

Abstract | Links:

Saha P, Fortin S, Leblanc V, Parent S, Asselin E, Berube G

Design, synthesis, cytocidal activity and estrogen receptor α affinity of doxorubicin conjugates at 16α-position of estrogen for site-specific treatment of estrogen receptor positive breast cancer

Journal Article

Steroids, 77 (11), 2012.

Abstract | Links:

Turcotte V, Fortin S, Vevey F, Coulombe Y, Lacroix J, Cote MF, Masson JY, C-Gaudreault R

Synthesis, biological evaluation, and structure-activity relationships of novel substituted N-phenyl ureidobenzenesulfonate derivatives blocking cell cycle progression in S-phase and inducing DNA double-strand breaks

Journal Article

J Med Chem, 55 (13), 2012.

Abstract | Links:

Fortin S, Wei L, Moreau E, Lacroix J, Cote MF, Petitclerc E, Kotra LP, Gaudreault RC

Substituted phenyl 4-(2-oxoimidazolidin-1-yl)benzenesulfonamides as antimitotics. Antiproliferative, antiangiogenic and antitumoral activity, and quantitative structure-activity relationships

Journal Article

Eur J Med Chem, 46 (11), 2011.

Abstract | Links:

Fortin S, Bouchon B, Chambon C, Lacroix J, Moreau E, Chezal JM, Degoul F, C-Gaudreault R

Characterization of the covalent binding of N-phenyl-N'-(2-chloroethyl)ureas to {beta}-tubulin: importance of Glu198 in microtubule stability

Journal Article

J Pharmacol Exp Ther, 336 (2), 2011.

Abstract | Links:

42 entries « ‹ 3 of 5 › »
Signaler des ajouts ou des modifications

Active projects

  • Développement et optimisation de nouveaux agents anticancéreux ciblant les cancers humains réfractaires aux traitements actuels., from 2023-07-01 to 2026-06-30
  • Eleclazine: “Boosting” efficacy and safety of the antineoplastic drug Alpelisib (Piqray®)?, from 2023-01-01 to 2024-12-30
  • Les phénylureidobenzènesulfonates, une nouvelle thérapie de différenciation pour le traitement de la leucémie myéloïde aiguë : preuve de concept, from 2020-02-01 to 2024-01-31
  • L’AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1, from 2021-10-01 to 2026-09-30
  • Pharmacological optimization of OpKemo, a silica-based nanoparticle platform for oncology, from 2022-01-31 to 2024-03-31

Recently finished projects

  • Appui financier du Fonds de recherche de l’Hôpital Saint-François d'Assise pour le support de doctorants.es au laboratoire du Dr Sébastien Fortin, from 2020-05-01 to 2022-04-30
  • Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site, from 2016-04-01 to 2023-03-31
  • Computational design, synthesis, and screening of FUT8 inhibitors as new anticancer agents_Fortin, from 2022-09-01 to 2023-08-31
  • Conception de nouveaux agents anticancéreux ciblant les mécanismes, from 2018-07-01 to 2022-06-30
  • Conception de nouveaux agents anticancéreux ciblant les mécanismes de réparation et de réplication de l'ADN en vue de leur utilisation en médecine personnalisée, from 2018-07-01 to 2022-06-30
  • Design and synthesis of FUT8 inhibitors as new anticancer agents - Fortin, from 2022-04-01 to 2023-07-31
  • Projet parent « Design and synthesis of FUT8 inhibitors as new anticancer agents, from 2022-04-01 to 2023-07-31
Data provided by the Université Laval research projects registery